



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
James D. Lechleiter
✉ lechleiter@uthscsa.edu

†These authors share first authorship

RECEIVED 16 January 2024
ACCEPTED 18 January 2024
PUBLISHED 29 January 2024

CITATION
Fisher ES, Chen Y, Sifuentes MM,
Stubblefield JJ, Lozano D, Holstein DM, Ren J,
Davenport M, DeRosa N, Chen T-p, Nickel G,
Liston TE and Lechleiter JD (2024)
Corrigendum: Adenosine A1R/A3R agonist
AST-004 reduces brain infarction in mouse
and rat models of acute ischemic stroke.
Front. Stroke 3:1371734.
doi: 10.3389/fstro.2024.1371734

COPYRIGHT
© 2024 Fisher, Chen, Sifuentes, Stubblefield,
Lozano, Holstein, Ren, Davenport, DeRosa,
Chen, Nickel, Liston and Lechleiter. This is an
open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](#). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
terms.

Corrigendum: Adenosine A1R/A3R agonist AST-004 reduces brain infarction in mouse and rat models of acute ischemic stroke

Elizabeth S. Fisher^{1†}, Yanan Chen^{1†}, Mikaela M. Sifuentes^{1†},
Jeremy J. Stubblefield¹, Damian Lozano¹, Deborah M. Holstein¹,
JingMei Ren², Matthew Davenport², Nicholas DeRosa¹,
Tsong-pei Chen¹, Gerard Nickel¹, Theodore E. Liston³ and
James D. Lechleiter^{1*}

¹Department of Cell Systems and Anatomy, University of Texas Health at San Antonio, San Antonio, TX, United States, ²NeuroVasc Preclinical Services, Inc., Lexington, MA, United States, ³Astrocyte Pharmaceuticals Inc., Cambridge, MA, United States

KEYWORDS

Adora3, stroke treatment, mitochondrial metabolism, ATP, astrocytes

A corrigendum on

Adenosine A1R/A3R agonist AST-004 reduces brain infarction in mouse and rat models of acute ischemic stroke

by Fisher, E. S., Chen, Y., Sifuentes, M. M., Stubblefield, J. J., Lozano, D., Holstein, D. M., Ren, J., Davenport, M., DeRosa, N., Chen, T. -p., Nickel, G., Liston, T. E., and Lechleiter, J. D. (2022). *Front. Stroke* 1:1010928. doi: 10.3389/fstro.2022.1010928

In the published article, there was an error in the Funding statement. The funding source for coauthor Jeremy J. Stubblefield was not included. Original text: This study received funding from Astrocyte Pharmaceuticals, Inc. The correct Funding statement appears below.

Funding

This study received funding from Astrocyte Pharmaceuticals, Inc. JS was supported by NIH IRACDA training grant K12 GM111726.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.